Fig. 1From: Liquid biopsy as an option for predictive testing and prognosis in patients with lung cancerInclusion for variant agreement between tumor and plasma samples. The total study cohort consisted of patients with cfDNA AVENIO NGS performed (n = 77). One cfDNA plasma sample was excluded due to too low unique molecular depth (< 500×). For agreement between tumor or benign lung tissue and paired plasma, clinical variant analysis data from DNA and RNA NGS was retrieved. When tumor tissue or cytology was insufficient for NGS, clinical variant analysis data was retrieved from qPCR or FISH for DNA or RNA, respectively. A subset of patients (n = 24), where additional tumor material was available, was also analyzed with the corresponding AVENIO kit as for plasmaBack to article page